Download PDF
Thromb Haemost 1998; 79(03): 491-494
DOI: 10.1055/s-0037-1614931
Review Articles
Schattauer GmbH

Low-molecular Weight Heparin Reduces the Generation and Activity of Thrombin in Unstable Coronary Artery Disease

Mats Ernofsson
3   Laboratory for Coagulation Research, Department of Clinical Laboratory Sciences, Clinical Chemistry, University Hospital Uppsala, Sweden
,
Finn Strekerud
1   Department of Medicine, Aker University Hospital, Oslo, Norway
,
Henrik Toss
2   Department of Cardiology, University Hospital, Uppsala, Sweden
,
Ulrich Abildgaard
1   Department of Medicine, Aker University Hospital, Oslo, Norway
,
Lars Wallentin
2   Department of Cardiology, University Hospital, Uppsala, Sweden
,
Agneta Siegbahn
3   Laboratory for Coagulation Research, Department of Clinical Laboratory Sciences, Clinical Chemistry, University Hospital Uppsala, Sweden
› Author Affiliations
Further Information

Publication History

Received 26 May 1997

Accepted after resubmission 27 October 1997

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Unstable coronary artery disease (UCAD) is associated with an increased risk of further coronary events. In the FRISC study, the risk was decreased during treatment with a high, twice-daily, dose of dalteparin, a low-molecular-weight heparin. However, lowering the dose resulted in raised risk of recurrences. To investigate the underlying pathophysiology, the thrombin generation and activity in patients with UCAD randomized to a 6-week placebo-controlled treatment with dalteparin were evaluated.

Plasma prothrombin fragment 1+2 (F1+2) (n = 342), thrombin-antithrombin complex (TAT) (n = 186) and soluble fibrin (SF) (n = 298) were analyzed before and during treatment with dalteparin/placebo administered subcutaneously, 120 IU/kg bw twice daily for 5-8 days and 7,500 IU once daily the following 35-40 days. High-dose treatment with dalteparin resulted in significantly reduced levels of all coagulation markers, demonstrating diminished thrombin generation and activity. When reducing the dalteparin dose, plasma TAT and SF remained low, indicating minimal fibrin formation. However, F1+2 increased during this period, though the level at day 45 was still lower than in the placebo group. In the placebo group elevated thrombin generation and activity persisted during the entire period.

In conclusion, high-dose treatment with dalteparin twice daily resulted in significantly reduced thrombin generation and activity. However, after changing to a lower, once-daily dose, the treatment was not sufficient in preventing a return to a procoagulable state. These changes of the coagulation activity might explain the changes in event rate observed during dalteparin treatment.

 

  • References

  • 1 Bresnahan DR, Davis JL, Holmes Jr. DR, Smith HC. Angiographic occur-rence and clinical correlates of intraluminal coronary artery thrombus: role of unstable angina.. J Am Coll Cardiol 1985; 6: 285-9.
    CrossrefPubMedGoogle Scholar
  • 2 Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris.. J Am Coll Cardiol 1985; 5: 609-16.
    CrossrefPubMedGoogle Scholar
  • 3 Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina.. J Am Coll Cardiol 1986; 7: 472-8.
    CrossrefPubMedGoogle Scholar
  • 4 Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis.. Circulation 1985; 71: 912-8.
    CrossrefPubMedGoogle Scholar
  • 5 Munkvad S, Jespersen J, Gram J, Kluft C. Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium.. J Intern Med 1990; 228: 361-6.
    CrossrefPubMedGoogle Scholar
  • 6 Neri Serneri GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F, Rostagno C, Boddi M, Gensini GF. Transient intermittent lymphocyte activation is responsible for the instability of angina.. Circulation 1992; 86: 790-7.
    CrossrefPubMedGoogle Scholar
  • 7 Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina.. N Engl J Med 1994; 331: 417-24.
    CrossrefPubMedGoogle Scholar
  • 8 Théroux P, Ouimet H, McCans J, Latour J-G, Joly P, Lévy G, Pelletier E, Juneau M, Stasiak J, de Guise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina.. N Engl J Med 1988; 319: 1105-11.
    CrossrefPubMedGoogle Scholar
  • 9 The RISC group.. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.. Lancet 1990; 336: 827-30.
    CrossrefPubMedGoogle Scholar
  • 10 Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin.. N Engl J Med 1992; 327: 141-5.
    CrossrefPubMedGoogle Scholar
  • 11 Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.. Circulation 1994; 90: 61-8.
    CrossrefPubMedGoogle Scholar
  • 12 Granger CB, Miller JM, Bovill EG, Gruber A, Tracy RP, Krucoff MW, Green C, Berrios E, Harrington RA, Ohman EM, Califf RM. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.. Circulation 1995; 91: 1929-35.
    CrossrefPubMedGoogle Scholar
  • 13 Boneu B. Low molecular weight heparin therapy: is monitoring needed?. Thromb Haemost 1994; 72: 330-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Barrowcliffe TW. Low molecular weight heparin(s).. Br J Haematol 1995; 90: 1-7.
    CrossrefPubMedGoogle Scholar
  • 15 Fragmin during instability in coronary artery disease (FRISC) study group.. Low-molecular-weight heparin during instability in coronary artery disease.. Lancet 1996; 347: 561-8.
    CrossrefPubMedGoogle Scholar
  • 16 Al-Nozha M, Gader AMA, Al-Momen AK, Noah MS, Jawaid M, Arafa M. Haemostatic variables in patients with unstable angina.. Int J Cardiol 1994; 43: 269-77.
    CrossrefPubMedGoogle Scholar
  • 17 Annex BH, Denning SM, Channon KM, Sketch Jr. MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes.. Circulation 1995; 91: 619-22.
    CrossrefPubMedGoogle Scholar
  • 18 Neri Serneri GG, Gensini GF, Abbate R, Laureano R, Parodi O. Is raised plasma fibrinopeptide A a marker of acute coronary insufficiency?. Lancet 1980; ii: 982-3.
    PubMedGoogle Scholar
  • 19 Théroux P, Latour J-G, Léger-Gauthier C, de Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris.. Circulation 1987; 75: 156-62.
    CrossrefPubMedGoogle Scholar
  • 20 Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.. Blood 1993; 82: 513-20.
    PubMedGoogle Scholar
  • 21 Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor.. Thromb Res 1996; 83: 307-20.
    CrossrefPubMedGoogle Scholar
  • 22 Leatham EW, Bath PMW, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease.. Br Heart J 1995; 73: 10-3.
    PubMedGoogle Scholar
  • 23 Jude B, Agraou B, McFadden EP, Susen S, Bauters C, Lepelley P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina.. Circulation 1994; 90: 1662-8.
    CrossrefPubMedGoogle Scholar
  • 24 Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina.. Circulation 1996; 94: 874-7.
    CrossrefPubMedGoogle Scholar
  • 25 Hansen J-B, Sandset PM, Huseby KR, Huseby N-E, Nordøy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.. Thromb Haemost 1996; 76: 703-9.
    Article in Thieme ConnectPubMedGoogle Scholar